- Home
- PSHG vs PASG Comparison
PSHG vs PASG Comparison
Compare PSHG & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSHG
- PASG
- Stock Information
- Founded
- PSHG 2010
- PASG 2017
- Country
- PSHG Greece
- PASG United States
- Employees
- PSHG N/A
- PASG N/A
- Industry
- PSHG Marine Transportation
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- PSHG Consumer Discretionary
- PASG Health Care
- Exchange
- PSHG Nasdaq
- PASG Nasdaq
- Market Cap
- PSHG 22.8M
- PASG 20.3M
- IPO Year
- PSHG N/A
- PASG 2020
- Fundamental
- Price
- PSHG $1.88
- PASG $7.03
- Analyst Decision
- PSHG
- PASG Strong Buy
- Analyst Count
- PSHG 0
- PASG 4
- Target Price
- PSHG N/A
- PASG $59.25
- AVG Volume (30 Days)
- PSHG 119.3K
- PASG 31.7K
- Earning Date
- PSHG 11-06-2025
- PASG 11-12-2025
- Dividend Yield
- PSHG N/A
- PASG N/A
- EPS Growth
- PSHG 5.84
- PASG N/A
- EPS
- PSHG 1.56
- PASG N/A
- Revenue
- PSHG $84,042,000.00
- PASG N/A
- Revenue This Year
- PSHG N/A
- PASG N/A
- Revenue Next Year
- PSHG $17.95
- PASG N/A
- P/E Ratio
- PSHG $1.15
- PASG N/A
- Revenue Growth
- PSHG N/A
- PASG N/A
- 52 Week Low
- PSHG $1.31
- PASG $5.12
- 52 Week High
- PSHG $2.34
- PASG $26.60
- Technical
- Relative Strength Index (RSI)
- PSHG 50.87
- PASG 50.96
- Support Level
- PSHG $1.77
- PASG $6.82
- Resistance Level
- PSHG $1.95
- PASG $7.45
- Average True Range (ATR)
- PSHG 0.09
- PASG 0.46
- MACD
- PSHG -0.01
- PASG -0.02
- Stochastic Oscillator
- PSHG 47.83
- PASG 40.00
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.